# Neurology (movement disorders) Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Muhammad Ali (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX001-SYN
- Date: 2026-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Moreau, MD
- Calendar frame: modern shifted

- To: Kwame Asante, MD, Neurology (movement disorders)
- Urgency: Routine, within four weeks, on the same day as his four-week primary care check

## Referral question

Young-onset Parkinson's disease, diagnosed twelve years ago at 42, in a 54-year-old man whose slowness of movement now limits daily tasks on a modest levodopa dose. Please review the diagnosis, advise on the levodopa dose or another agent, and plan rehabilitation for his soft speech and gait. **S**

## Questions for the consultant

1. Does he meet the MDS criteria for Parkinson's disease, given the young onset and the earlier description of a parkinsonian syndrome related to boxing, and is brain imaging needed?
2. Should levodopa be increased, or another agent added, for the bradykinesia?
3. What rehabilitation do you advise for his soft speech and his gait and balance?
4. Should genetic testing be offered?
5. How often should he be followed, and by whom?

## Pertinent history

Parkinsonism diagnosed at 42, three years after he retired from professional boxing; at the time it was described as a parkinsonian syndrome possibly related to repeated head blows, and that link has never been settled. On carbidopa-levodopa 25/100 mg one tablet three times daily, often taken with meals, for many years. Today, in the on state: MDS-UPDRS Part III 30, Hoehn and Yahr stage 2.5, with bilateral bradykinesia and rigidity worse on the right, right-hand rest tremor, reduced facial expression and blinking, and soft, monotone speech. No dyskinesia, wearing-off, or freezing. No falls; Timed Up and Go 13 seconds; recovers after three steps on the pull test. Blood pressure 130/80 mmHg supine and 122/78 mmHg standing at 3 minutes. MoCA 27 of 30, PHQ-9 3, EAT-10 2, negative REM sleep behavior disorder and impulse-control screens, and Epworth score 6. Blood count, chemistry, vitamin B12, and TSH normal. No dopamine-blocking drugs. **S**

- Muhammad Ali was born Cassius Clay in Louisville, Kentucky, on January 17, 1942. **D**
- In 1984, at age 42 and three years after he retired from boxing, Ali was diagnosed with a parkinsonian condition by the neurologist Stanley Fahn in New York; it has been publicly described as Parkinson's disease since. **D**
- The diagnosing neurologist later said publicly that slowness of movement was Ali's main limitation at the time of diagnosis, with a masked face, decreased blinking, a typical parkinsonian tremor, and a shuffling gait, and that some features were too early for classic Parkinson's disease. **D**
- In a 1996 television interview, Ali's physician Dennis Cope described his condition as Parkinson's syndrome attributed to pugilistic brain syndrome from boxing, and said testing showed his cognitive function had not declined: "His mind is fine." **D**
- Whether boxing caused Ali's Parkinson's disease is disputed. The diagnosing neurologist thought the early symptoms were probably caused by repeated blows to the head but could not be certain; his later physician Abraham Lieberman did not think boxing contributed, though he was not a hundred percent certain; and the director of the Muhammad Ali Parkinson Center said there was no medical evidence that boxing contributed. **R**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin: 14.6 g/dL; Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 87 mL/min/1.73 m²; Glucose: 92 mg/dL; Calcium: 9.5 mg/dL; Vitamin B12: 512 pg/mL; TSH: 1.8 mIU/L; MoCA: 27; PHQ-9: 3. All results are synthetic.

BP 128/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 102 kg; BMI 28 kg/m². All vital signs are synthetic.

## Current medications

- Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily **S**

## Plan so far

- Review the levodopa dose and timing at every visit for slowness, wearing-off, and dyskinesia; take doses 30 minutes before meals; check supine and three-minute standing blood pressure after any change; avoid dopamine-blocking drugs such as metoclopramide, prochlorperazine, and most antipsychotics. Guideline: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Monitor on the CMID schedule: motor examination, Hoehn and Yahr stage, fall check, psychosis and impulse-control questions, and medication review every visit; cognition, mood, sleep, autonomic symptoms, swallowing, speech, and driving yearly; dental examination every six months. Guideline: MDS clinical diagnostic criteria for Parkinson's disease (2015); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Advance care planning: name a health care agent and record goals of care, and revisit with any change in stage. Guideline: CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
